Frontier Medicines Appoints Gerardo Ubaghs as Chief Financial Officer and Announces $20 Million Series C Extension
25 juin 2024 07h00 HE
|
Frontier Medicines
Gerardo Ubaghs brings high-profile global biopharma strategic and capital markets experience as newly appointed Chief Financial Officer (CFO)Company adds $20 million to close oversubscribed Series C...
Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting
09 avr. 2024 16h30 HE
|
Frontier Medicines
- Pre-clinical results demonstrate the combination of FMC-376 with PD-1 immunotherapy increases survival and response rates compared to PD-1 alone - FMC-376 is broadly active in KRASG12C mutant...
Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024
06 mars 2024 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance...
Frontier Medicines to Participate in Upcoming Investor Conferences
27 févr. 2024 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
22 févr. 2024 16h01 HE
|
Frontier Medicines
Frontier Medicines Series C close and first patient dosed
Frontier Medicines to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
Frontier Medicines Announces Appointment of Andrew Krivoshik, M.D., Ph.D., as Chief Medical Officer
08 mai 2023 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational...
Frontier Medicines Presents New Preclinical Data on its Development Candidate, FMC-376, a Dual KRASG12C Inhibitor, at the 2023 AACR Annual Meeting
16 avr. 2023 15h00 HE
|
Frontier Medicines
-FMC-376 is a highly selective, direct dual inhibitor designed to rapidly and completely block both the active and inactive forms of KRASG12C and overcome the limitations seen with single-acting...
Frontier Medicines to Spotlight Lead Candidate, Novel Dual KRASG12C Inhibitor FMC-376, and the Frontier™ Platform at the 2023 AACR Annual Meeting
14 mars 2023 17h56 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...
Frontier Medicines Expands Leadership Team with Addition of Christo Shalish as Head of Business Development
28 févr. 2023 08h00 HE
|
Frontier Medicines
BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough...